Kareo vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Merged with PatientPop → Tebra 2021; $222M funding; $1B+ valuation; $72M 2023 (Golub); 100K providers; 90M patients; 1,000 employees; practice management/EHR leader
About
Kareo was founded in 2004 by Dan Rodrigues to build purpose-designed practice management and billing software for independent physician practices — a segment underserved by legacy healthcare IT vendors focused on hospital systems. The platform addressed the full administrative workflow of a small medical practice: appointment scheduling, patient registration, insurance eligibility verification, charge capture, medical billing, and accounts receivable management. Kareo also developed an integrated EHR module, making it one of the few vendors to combine clinical documentation and practice management in a cloud-native platform accessible to solo practitioners.\n\nKareo's products included Kareo Billing for RCM, Kareo Clinical for EHR and documentation, and Kareo Engage for patient communication and online reputation management. The platform served primary care, mental health, physical therapy, and chiropractic specialties. Its cloud-based delivery — accessible via browser and mobile without on-premises infrastructure — resonated strongly with independent practices managing lean overhead. A managed RCM service and QuickBooks integration rounded out the offering.\n\nKareo merged with PatientPop, a digital practice growth platform, in 2021 to form Tebra — targeting the full lifecycle of independent practice management from marketing through billing. The combined company has raised $222 million in total funding, achieved a $1 billion+ valuation, and serves over 100,000 providers across 90 million patients. Tebra continues operating the Kareo brand for billing and EHR while integrating PatientPop's digital presence capabilities into a unified independent practice growth platform.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.